https://scholars.lib.ntu.edu.tw/handle/123456789/543537
標題: | Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer | 作者: | Chao Y. KUN-HUEI YEH Chang C.J. Chen L.T. Chao T.Y. Wu M.F. Chang C.S. Chang J.Y. Chung C.Y. Kao W.Y. Hsieh R.K. ANN-LII CHENG |
公開日期: | 2004 | 卷: | 91 | 期: | 3 | 起(迄)頁: | 453-458 | 來源出版物: | British Journal of Cancer | 摘要: | To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m-2 2-h intravenous infusion, and 5-FU 2600 mg m-2 plus FA 300 mg m-2 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22-75). In all, 52 patients (94.5%) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8-70.3%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-up time of 24.0 months. Major grades 3-4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%). Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxalipiatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated. ? 2004 Cancer Research UK. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-4243135036&doi=10.1038%2fsj.bjc.6601985&partnerID=40&md5=d1084cc5af015f79d077cc577eebfa81 https://scholars.lib.ntu.edu.tw/handle/123456789/543537 |
ISSN: | 0007-0920 | DOI: | 10.1038/sj.bjc.6601985 | SDG/關鍵字: | fluorouracil; folinic acid; oxaliplatin; adult; advanced cancer; age; aged; alopecia; anemia; anorexia; article; body weight disorder; cancer chemotherapy; cancer growth; cancer patient; cancer radiotherapy; cancer surgery; cancer survival; clinical trial; confidence interval; controlled clinical trial; controlled study; diarrhea; drug efficacy; drug infusion; drug safety; drug use; evaluation; febrile neutropenia; female; fever; follow up; gastrointestinal disease; heart disease; hematologic disease; histology; human; infection; leukopenia; major clinical study; male; metastasis; nausea; neuropathy; neurotoxicity; neutropenia; phase 2 clinical trial; priority journal; recurrent cancer; stomach cancer; stomatitis; survival time; thrombocytopenia; treatment outcome; treatment withdrawal; vomiting; weight reduction; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Nervous System; Neutropenia; Organoplatinum Compounds; Stomach Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。